Targeting hypoxia-inducible factor 1 (HIF-1) signaling with natural products toward cancer chemotherapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting hypoxia-inducible factor 1 (HIF-1) signaling with natural products toward cancer chemotherapy
Authors
Keywords
-
Journal
JOURNAL OF ANTIBIOTICS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-07-30
DOI
10.1038/s41429-021-00451-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ways into Understanding HIF Inhibition
- (2021) Tina Schönberger et al. Cancers
- Biosynthesis and Chemical Diversification of Verucopeptin Leads to Structural and Functional Versatility
- (2020) Lei Zhang et al. ORGANIC LETTERS
- Pharmacologic Targeting of Hypoxia-Inducible Factors
- (2019) Gregg L. Semenza Annual Review of Pharmacology and Toxicology
- Target Identification of the Marine Natural Products Dictyoceratin-A and -C as Selective Growth Inhibitors in Cancer Cells Adapted to Hypoxic Environments
- (2019) Takashi Kawachi et al. Marine Drugs
- Ubiquitin carboxyl‐terminal hydrolase L1 promotes hypoxia‐inducible factor 1‐dependent tumor cell malignancy in spheroid models
- (2019) Xuebing Li et al. CANCER SCIENCE
- Regulatory mechanisms of hypoxia-inducible factor 1 activity: Two decades of knowledge
- (2018) Sho Koyasu et al. CANCER SCIENCE
- Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma
- (2018) Kevin D. Courtney et al. JOURNAL OF CLINICAL ONCOLOGY
- The lignan manassantin is a potent and specific inhibitor of mitochondrial complex I and bioenergetic activity in mammals
- (2017) Yibao Ma et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Hypoxia-inducible factor-1 (HIF-1) inhibitors from the last decade (2007 to 2016): A “structure-activity relationship” perspective
- (2017) Deepak Bhattarai et al. MEDICINAL RESEARCH REVIEWS
- A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma
- (2016) Eli M. Wallace et al. CANCER RESEARCH
- Hypoxia‐inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype
- (2016) Gregg L Semenza EMBO JOURNAL
- Natural products-prompted chemical biology: phenotypic screening and a new platform for target identification
- (2016) Hideaki Kakeya NATURAL PRODUCT REPORTS
- On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models
- (2016) Hyejin Cho et al. NATURE
- Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1
- (2016) Heba Alshaker et al. Oncotarget
- Design, synthesis, and structure–activity relationships of 1-ethylpyrazole-3-carboxamide compounds as novel hypoxia-inducible factor (HIF)-1 inhibitors
- (2015) Yorinobu Yasuda et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Structure Elucidation of Verucopeptin, a HIF-1 Inhibitory Polyketide–Hexapeptide Hybrid Metabolite from an Actinomycete
- (2015) Aya Yoshimura et al. ORGANIC LETTERS
- Marine spongian sesquiterpene phenols, dictyoceratin-C and smenospondiol, display hypoxia-selective growth inhibition against cancer cells
- (2014) Masayoshi Arai et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- A Group of Novel HIF-1α Inhibitors, Glyceollins, Blocks HIF-1α Synthesis and Decreases Its Stability via Inhibition of the PI3K/AKT/mTOR Pathway and Hsp90 Binding
- (2014) Sun-Hee Lee et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors
- (2013) Woondong Jeong et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)
- (2010) Michael R. Harrison et al. INVESTIGATIONAL NEW DRUGS
- A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma
- (2010) Simon Pacey et al. INVESTIGATIONAL NEW DRUGS
- Identification of HSP60 as a Primary Target ofo-Carboranylphenoxyacetanilide, an HIF-1α Inhibitor
- (2010) Hyun Seung Ban et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Natural compounds and the hypoxia-inducible factor (HIF) signalling pathway
- (2009) Bogdan Manolescu et al. BIOCHIMIE
- Development of HIF-1 inhibitors for cancer therapy
- (2009) Barbara Onnis et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
- (2009) K. Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1
- (2008) M. Y. Koh et al. MOLECULAR CANCER THERAPEUTICS
- A RNA antagonist of hypoxia-inducible factor-1 , EZN-2968, inhibits tumor cell growth
- (2008) L. M. Greenberger et al. MOLECULAR CANCER THERAPEUTICS
- Therapeutic strategy targeting the mTOR-HIF-1α-VEGF pathway in ovarian clear cell adenocarcinoma
- (2008) Masaki Miyazawa et al. PATHOLOGY INTERNATIONAL
- Digoxin and other cardiac glycosides inhibit HIF-1 synthesis and block tumor growth
- (2008) H. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation
- (2008) X. Lin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started